Resumix

Remix Therapeutics is a biotechnology company focused on developing small molecule therapies that modulate RNA processing to treat a variety of diseases, including cancer and rare genetic disorders. The company's proprietary REMIX platform leverages high-throughput screening and advanced computational tools to identify and target specific RNA sequences and structures. By influencing how RNA is spliced, translated, or degraded, Remix aims to address disease drivers that have historically been considered undruggable. The company is currently advancing a pipeline of preclinical programs and has established significant partnerships with major pharmaceutical companies to expand the reach of its technology.